Elicio Therapeutics, Inc (ELTX)

Several events have impacted Elicio Therapeutics' stock price in the past six months. A delay in clinical trial data readout for the Phase 2 AMPLIFY-7P trial introduced investor uncertainty. Concerns over the company's financial runway have been a risk factor, although recent financing extended it through the second quarter of 2026. Despite encouraging preliminary clinical data, the market remained cautious. Technical indicators displayed bearish trends, contributing to a stock movement of approximately -13.2%. Elicio Therapeutics was upgraded to a Zacks Rank #2 (Buy) in December 2025. Elicio Therapeutics secured $10 million in financing around June 2025.

There is no information available to suggest demand seasonality for Elicio Therapeutics, Inc.'s products and services. Demand is primarily driven by clinical trial progression, potential regulatory approvals, and the prevalence of targeted cancer types.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases, operating in the Biotechnology: Pharmaceutical Preparations industry. The company utilizes its proprietary Amphiphile (AMP) platform to deliver immunotherapeutics directly to the lymph nodes. Its major product candidates include ELI-002, a multivalent lymph node-targeted AMP peptide vaccine in Phase II clinical trials targeting KRAS-driven cancers; ELI-007, a similar vaccine in preclinical studies for BRAF-driven cancers; and ELI-008, a vaccine in preclinical studies for TP53 expressing cancers.

Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. The company's primary focus is currently within the U.S.

Elicio Therapeutics' brand reputation is closely tied to its clinical trial progress and financial stability. While preliminary clinical data for ELI-002 has been encouraging, market skepticism persists as investors await definitive efficacy outcomes. Concerns about the company's financial runway have also been a factor. An analyst from H.C. Wainwright reiterated a "Buy" rating in April 2025, citing financial stability and promising developments with ELI-002 7P. An upgrade to a Zacks Rank #2 (Buy) in December 2025 suggests an improving earnings outlook.

Elicio Therapeutics, Inc. has a mixed ownership structure. Approximately 9.37% to 11% of the company's stock is owned by institutional investors, with major shareholders including Knoll Capital Management, LLC, and Vanguard Group Inc. Insiders own approximately 32.06% to 33% of the shares, with Yekaterina Chudnovsky being the largest individual shareholder. Retail investors hold a substantial stake, ranging from 24.68% to 58.57% of the company.